Affiliation: University of Texas Southwestern Medical Center
- Controlled-release carvedilol: a concluding perspectiveMilton Packer
Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
Am J Cardiol 98:67L-69L. 2006
- Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarctionMilton Packer
Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
Am J Cardiol 98:39L-45L. 2006..These data demonstrate that the new carvedilol CR formulation given once daily is equivalent to the currently available carvedilol IR formulation given twice daily in patients with heart failure and asymptomatic post-MI LVD...
- Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failureMilton Packer
University of Texas Southwestern Medical Center, Dallas, Texas 75390 8822, USA
J Am Coll Cardiol 47:2245-52. 2006..This study sought to assess the potential utility of impedance cardiography (ICG) in predicting clinical deterioration in ambulatory patients with heart failure (HF)...
- Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialFranz Hartmann
Medizinische Klinik II, Universitaetsklinikum Schleswig Holstein, Campus Luebeck, Ratzeburger Allee 160, D 23538 Luebeck, Germany
Circulation 110:1780-6. 2004....
- Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United KingdomSimon Stewart
Division of Health Sciences, University of South Australia, City East Campus, Adelaide 5000, Australia
Int J Cardiol 100:143-9. 2005..The aim of this study was to determine the effects of carvedilol on the costs related to the treatment of severe chronic heart failure (CHF)...
- Prognostic benefit of beta-blockers in patients not receiving ACE-InhibitorsHenry Krum
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne 3004, Australia
Eur Heart J 26:2154-8. 2005..The magnitude of the prognostic benefit of BBs in the absence of ACE-I or ARB has not as yet been determined...
- NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudyFranz Hartmann
Medizinische Klinik II, Universitaetsklinikum Schleswig Holstein, Campus Luebeck, Luebeck, Germany
Eur J Heart Fail 6:343-50. 2004..Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated with carvedilol or placebo...
- Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trialMilton Packer
Division of Circulatory Physiology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Card Fail 9:429-43. 2003....
- Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS studyHenry Krum
Monash University, Melbourne, Australia
Am Heart J 151:55-61. 2006..We therefore examined this question in the COPERNICUS study of 2289 patients with severe CHF receiving the beta1-beta2/alpha1 blocker carvedilol compared with placebo...
- The Seattle Heart Failure Model: prediction of survival in heart failureWayne C Levy
University of Washington, Seattle, WA 98177, USA
Circulation 113:1424-33. 2006....
- Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS StudyHenry Krum
Dept of Medicine and Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, 3181 Australia
JAMA 289:712-8. 2003..Beta-blockers remain underused despite their established utility for improving outcome in heart failure. Concerns that initiation of treatment produces few immediate benefits and may have important risks may be deterring widespread use...
- Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockersTimothy J Vittorio
Division of Circulatory Physiology, Columbia Presbyterian Medical Center, New York, NY 10032, USA
Circulation 107:290-3. 2003..Accordingly, we compared the vasopressor response to infused Ang II in patients treated with carvedilol and metoprolol, a selective beta-antagonist...
- Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyMilton Packer
College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Circulation 106:2194-9. 2002..Beta-blocking agents improve functional status and reduce morbidity in mild-to-moderate heart failure, but it is not known whether they produce such benefits in severe heart failure...
- Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failureEric B Stanton
Division of Cardiology, McMaster University and St Joseph s Hospital, Hamilton, Ontario
Can J Cardiol 21:39-43. 2005..Cardiac troponin I (cTnI) has been validated as a sensitive and specific marker of myocyte damage, and is elevated in some patients with congestive heart failure...
- Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) studyMariya P Tokmakova
Department of Cardiology, St George Hospital, Medical University Plovdiv, Plovdiv, Bulgaria
Circulation 110:3667-73. 2004..Future cardiovascular event rates and the relative response to therapy in persons with mild to moderate CKD are not well characterized...
- Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) studyJean L Rouleau
Montreal Heart Institute, University of Montreal, Montreal, Canada
J Am Coll Cardiol 43:1423-9. 2004..We sought to evaluate the influence of pretreatment systolic blood pressure (SBP) on the efficacy and safety of carvedilol in patients with chronic heart failure (CHF)...
- Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot studyMilton Packer
College of Physicians and Surgeons, Columbia University, New York, New York, USA
J Card Fail 11:12-20. 2005..Endothelin receptor antagonism produces favorable short-term hemodynamic effects in heart failure, but the clinical effects of longer term therapy have not been evaluated...
- Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanismsMathew S Maurer
Division of Circulatory Physiology, Columbia Universitry, 177 Fort Washington Avenue, MHB 5 435, New York, NY 10032, USA
J Card Fail 11:177-87. 2005..In view of the clinical heterogeneity of these patients, we hypothesized that subgroups of HFNEF patients may have different underlying pathophysiologic mechanisms...
- Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic studyScott D Solomon
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
Am Heart J 150:257-62. 2005..Angiotensin-converting enzyme (ACE) inhibition attenuates ventricular remodeling and improves ventricular function in heart failure patients. Vasopeptidase inhibition has shown similar effects in experimental models...
- Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trialsCamille G Frazier
Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Am Coll Cardiol 49:1450-8. 2007..This study sought to explore the gender-related differences in etiology and outcomes in chronic heart failure (HF) patients from 5 randomized trials...
- Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized TrialAlexandre Mebazaa
Department of Anesthesiology, Université Paris Diderot and Hospital Lariboisière AP HP, Paris, France
JAMA 297:1883-91. 2007..Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival...
- ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summarySharon A Hunt
American College of Cardiology American Heart Association Task Force on Practice Guidelines
J Heart Lung Transplant 21:189-203. 2002
- Diastolic heart failureMathew S Maurer
N Engl J Med 351:1143-5; author reply 1143-5. 2004
- Cardiac resynchronization in chronic heart failureWilliam T Abraham
Division of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington 40536 0284, USA
N Engl J Med 346:1845-53. 2002..We conducted a double-blind trial to evaluate this therapeutic approach...
- Diuretic resistance predicts mortality in patients with advanced heart failureGerald W Neuberg
Division of Circulatory Physiology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
Am Heart J 144:31-8. 2002..Because diuretic resistance can be overcome with escalating doses, the evaluation of CHF severity and prognosis may be incomplete without considering the intensity of therapy...
- Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)Milton Packer
Division of Circulatory Physiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Circulation 106:920-6. 2002..Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alone...
- The impossible task of developing a new treatment for heart failureMilton Packer
J Card Fail 8:193-6. 2002
- Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinanMark S Hansen
Division of Cardiology of the University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada
Am J Cardiol 90:969-73. 2002..Flosequinan treatment eliminates this association, highlighting the complexity of the relation between cardiac myocyte damage, drug treatment, and mortality...
- Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATEugene S Chung
The Lindner Center and Ohio Heart Health Center, Cincinnati 45219, USA
Circulation 107:3133-40. 2003..We evaluated the efficacy and safety of infliximab, a chimeric monoclonal antibody to TNFalpha, in patients with moderate-to-severe heart failure...
- A device is not a drugMarvin A Konstam
J Card Fail 9:155-7. 2003
- Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?Milton Packer
Division of Circulatory Physiology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA
Circulation 108:2950-3. 2003
- Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite studyAlan H B Wu
Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
Clin Chem 50:867-73. 2004..B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF)...
- Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)Douglas L Mann
Winters Center for Heart Failure Research, Baylor College of Medicine and the Houston VA, Houston, Tex 77030, USA
Circulation 109:1594-602. 2004..Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure...
- Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of AmericaMarvin A Konstam
J Card Fail 10:91-100. 2004
- The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsBarry M Massie
Cardiology Division, San Francisco Veterans Affairs Medical Center, CA 94121, USA
J Card Fail 10:101-12. 2004..The WATCH trial will help define the optimal approach to antithrombotic therapy in the contemporary management of patients with chronic heart failure resulting from left ventricular systolic dysfunction...
- Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Sumit R Majumdar
Division of General Internal Medicine, Department of Medicine, University of Alberta, 251 Medical Sciences Building, Edmonton, Alberta, Canada T6G 2H7
Clin Ther 26:694-703. 2004....
- Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradoxS William Tam
NitroMed, Inc, Lexington, Massachusetts 02421, USA
Clin Pharmacokinet 46:885-95. 2007....
- North and Central Texas Clinical and Translational Science Initiative (UL1)Milton Packer; Fiscal Year: 2007..abstract_text> ..